Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

CRISPR and Gene Editing: A Game-changer in Drug Development

Author(s): Abhishek Verma, Tarun Sharma and Ankit Awasthi*

Volume 30, Issue 15, 2024

Published on: 04 April, 2024

Page: [1133 - 1135] Pages: 3

DOI: 10.2174/0113816128298080240328053845

Price: $65

Abstract

CRISPR and gene editing technologies have emerged as transformative tools in medicine, offering unprecedented precision in targeting genetic disorders and revolutionizing drug development. This review explores the multifaceted impact of CRISPR across various medical domains, from hereditary diseases to infectious diseases and cancer. The potential of CRISPR in personalized medicine, therapeutic innovation, and pandemic prevention is highlighted, along with its role in reshaping traditional drug development processes. However, alongside its promise, ethical considerations loom large, particularly regarding germline editing and equitable access to treatments. The commercialization of CRISPR poses further challenges, raising questions about affordability and healthcare equity. Collaboration among scientists, policymakers, and the public is emphasized to navigate the ethical and societal implications of CRISPR responsibly. As the field advances, it is essential to ensure that the benefits of CRISPR are realized while addressing potential risks and maintaining a commitment to the well-being of future generations.

« Previous Next »
[1]
Adli M. The CRISPR tool kit for genome editing and beyond. Nat Commun 2018; 9(1): 1911.
[http://dx.doi.org/10.1038/s41467-018-04252-2] [PMID: 29765029]
[2]
Dimitri A, Herbst F, Fraietta JA. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing. Mol Cancer 2022; 21(1): 78.
[http://dx.doi.org/10.1186/s12943-022-01559-z] [PMID: 35303871]
[3]
Bhattacharya S, Satpati P. Insights into the mechanism of CRISPR/Cas9-based genome editing from molecular dynamics simulations. ACS Omega 2023; 8(2): 1817-37.
[http://dx.doi.org/10.1021/acsomega.2c05583] [PMID: 36687047]
[4]
Wang SW, Gao C, Zheng YM, et al. Current applications and future perspective of CRISPR/Cas9 gene editing in cancer. Mol Cancer 2022; 21(1): 57.
[http://dx.doi.org/10.1186/s12943-022-01518-8] [PMID: 35189910]
[5]
Abdelnour SA, Xie L, Hassanin AA, Zuo E, Lu Y. The potential of CRISPR/Cas9 gene editing as a treatment strategy for inherited diseases. Front Cell Dev Biol 2021; 9: 699597.
[http://dx.doi.org/10.3389/fcell.2021.699597] [PMID: 34977000]
[6]
Tsagkaraki E, Nicoloro SM, DeSouza T, et al. CRISPR-enhanced human adipocyte browning as cell therapy for metabolic disease. Nat Commun 2021; 12(1): 6931.
[http://dx.doi.org/10.1038/s41467-021-27190-y] [PMID: 34836963]
[7]
Binnie A, Fernandes E, Almeida-Lousada H, de Mello RA, Castelo-Branco P. CRISPR-based strategies in infectious disease diagnosis and therapy. Infection 2021; 49(3): 377-85.
[http://dx.doi.org/10.1007/s15010-020-01554-w] [PMID: 33393066]
[8]
Ding R, Long J, Yuan M, et al. CRISPR/Cas system: A potential technology for the prevention and control of COVID-19 and emerging infectious diseases. Front Cell Infect Microbiol 2021; 11: 639108.
[http://dx.doi.org/10.3389/fcimb.2021.639108] [PMID: 33968799]
[9]
Chan YT, Lu Y, Wu J, et al. CRISPR-Cas9 library screening approach for anti-cancer drug discovery: Overview and perspectives. Theranostics 2022; 12(7): 3329-44.
[http://dx.doi.org/10.7150/thno.71144] [PMID: 35547744]
[10]
Pascual-Gilabert M, Artero R, López-Castel A. The myotonic dystrophy type 1 drug development pipeline: 2022 edition. Drug Discov Today 2023; 28(3): 103489.
[http://dx.doi.org/10.1016/j.drudis.2023.103489] [PMID: 36634841]
[11]
Gostimskaya I. CRISPR-Cas9: A history of its discovery and ethical considerations of its use in genome editing. Biochemistry 2022; 87(8): 777-88.
[http://dx.doi.org/10.1134/S0006297922080090 ] [PMID: 36171658]
[12]
Brokowski C, Adli M. CRISPR ethics: Moral considerations for applications of a powerful tool. J Mol Biol 2019; 431(1): 88-101.
[http://dx.doi.org/10.1016/j.jmb.2018.05.044] [PMID: 29885329]
[13]
Nxumalo Z, Takundwa MM, Thimiri Govinda Raj DB. Patents, ethics, biosafety and regulation using CRISPR technology. Prog Mol Biol Transl Sci 2021; 181: 345-65.
[http://dx.doi.org/10.1016/bs.pmbts.2021.01.023] [PMID: 34127200]
[14]
Yunta ER, Vaschetto LM. Political, regulatory and ethical considerations of the CRISPR/Cas genome editing technology. CRISPR-/Cas9 based Genome Editing for Treating Genetic Disorders and Diseases. (1st Ed.). CRC Press 2022; pp. 71-84.
[15]
van Dongen JE, Berendsen JTW, Steenbergen RDM, Wolthuis RMF, Eijkel JCT, Segerink LI. Point-of-care CRISPR/Cas nucleic acid detection: Recent advances, challenges and opportunities. Biosens Bioelectron 2020; 166: 112445.
[http://dx.doi.org/10.1016/j.bios.2020.112445] [PMID: 32758911]
[16]
Hussen BM, Rasul MF, Abdullah SR, et al. Targeting miRNA by CRISPR/Cas in cancer: Advantages and challenges. Mil Med Res 2023; 10(1): 32.
[http://dx.doi.org/10.1186/s40779-023-00468-6] [PMID: 37460924]
[17]
Uddin F, Rudin CM, Sen T. CRISPR gene therapy: Applications, limitations, and implications for the future. Front Oncol 2020; 10: 1387.
[http://dx.doi.org/10.3389/fonc.2020.01387] [PMID: 32850447]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy